These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8865631)

  • 1. Phase delay measurements of distortion product otoacoustic emissions at 2f1-f2 and 2f2-f1 in human ears.
    Wable J; Collet L; Chéry-Croze S
    J Acoust Soc Am; 1996 Oct; 100(4 Pt 1):2228-35. PubMed ID: 8865631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locus of generation for the 2f1-f2 vs 2f2-f1 distortion-product otoacoustic emissions in normal-hearing humans revealed by suppression tuning, onset latencies, and amplitude correlations.
    Martin GK; Jassir D; Stagner BB; Whitehead ML; Lonsbury-Martin BL
    J Acoust Soc Am; 1998 Apr; 103(4):1957-71. PubMed ID: 9566319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of hearing loss using 2f2-f1 and 2f1-f2 distortion-product otoacoustic emissions.
    Fitzgerald TS; Prieve BA
    J Speech Lang Hear Res; 2005 Oct; 48(5):1165-86. PubMed ID: 16411804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distortion product otoacoustic emission test performance when both 2f1-f2 and 2f2-f1 are used to predict auditory status.
    Gorga MP; Nelson K; Davis T; Dorn PA; Neely ST
    J Acoust Soc Am; 2000 Apr; 107(4):2128-35. PubMed ID: 10790038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of primary frequencies ratio on distortion product otoacoustic emissions amplitude. II. Interrelations between multicomponent DPOAEs, tone-burst-evoked OAEs, and spontaneous OAEs.
    Moulin A
    J Acoust Soc Am; 2000 Mar; 107(3):1471-86. PubMed ID: 10738802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicomponent acoustic distortion product otoacoustic emission phase in humans. II. Implications for distortion product otoacoustic emissions generation.
    Moulin A; Kemp DT
    J Acoust Soc Am; 1996 Sep; 100(3):1640-62. PubMed ID: 8817892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications of different distortion product otoacoustic emission mechanisms from a detailed f1,f2 area study.
    Knight RD; Kemp DT
    J Acoust Soc Am; 2000 Jan; 107(1):457-73. PubMed ID: 10641654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the 2f
    Wen H; Bowling T; Meaud J
    Hear Res; 2018 Aug; 365():127-140. PubMed ID: 29801982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative distortion product otoacoustic emissions and hearing loss in a clinical population.
    Lind O
    Scand Audiol; 1999; 28(4):257-61. PubMed ID: 10572971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parameters to maximize 2f2-f1 distortion product otoacoustic emission levels.
    Horn JH; Pratt SR; Durrant JD
    J Speech Lang Hear Res; 2008 Dec; 51(6):1620-9. PubMed ID: 18664689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 2f1-f2 DPOAE and 2f2-f1 DPOAE fine structure in young and middle-aged adults.
    Rao A; Tusler EM; Formo A
    Int J Audiol; 2014 Mar; 53(3):165-73. PubMed ID: 24274649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distortion product otoacoustic emission (2f1-f2) amplitude as a function of f2/f1 frequency ratio and primary tone level separation in human adults and neonates.
    Abdala C
    J Acoust Soc Am; 1996 Dec; 100(6):3726-40. PubMed ID: 8969474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2f1-f2 distortion product otoacoustic emission latency: changes with frequency and level of primaries.
    Wable J; Collet L; Berger-Vachon C; Chéry-Croze S
    Audiology; 1997; 36(2):72-82. PubMed ID: 9099405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of generation of the 2f2-f1 distortion product otoacoustic emission in humans.
    Wilson HK; Lutman ME
    J Acoust Soc Am; 2006 Oct; 120(4):2108-15. PubMed ID: 17069308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicomponent acoustic distortion product otoacoustic emission phase in humans. I. General characteristics.
    Moulin A; Kemp DT
    J Acoust Soc Am; 1996 Sep; 100(3):1617-39. PubMed ID: 8817891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group delays of distortion product otoacoustic emissions in the guinea pig.
    Schneider S; Prijs VF; Schoonhoven R
    J Acoust Soc Am; 1999 May; 105(5):2722-30. PubMed ID: 10335624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Distortion Product Otoacoustic Emissions to Intracochlear Distortion Products Inferred from a Noninvasive Assay.
    Martin GK; Stagner BB; Dong W; Lonsbury-Martin BL
    J Assoc Res Otolaryngol; 2016 Aug; 17(4):271-87. PubMed ID: 27229002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The 2f1-f2 DPOAE amplitudes and latencies in the groups of older people with presbyacusis and young people with normal hearing].
    Namysłowski G; Morawski K; Urbaniec P; Lisowska G
    Otolaryngol Pol; 2000; 54(4):423-9. PubMed ID: 11070698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring Optimal Stimulus Frequency Ratio for Measurement of the Quadratic f2-f1 Distortion Product Otoacoustic Emission in Humans.
    Baiduc RR; Dhar S
    J Speech Lang Hear Res; 2018 Jul; 61(7):1794-1806. PubMed ID: 29946695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dependence of distortion-product otoacoustic emissions on primary levels in normal and impaired ears. I. Effects of decreasing L2 below L1.
    Whitehead ML; McCoy MJ; Lonsbury-Martin BL; Martin GK
    J Acoust Soc Am; 1995 Apr; 97(4):2346-58. PubMed ID: 7714254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.